Ascendis Pharma’s TransCon CNP Wins CHMP Backing for Pediatric Achondroplasia
EMA’s CHMP recommended Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged 2 and older with open growth plates. A European Commission decision is expected in the fourth quarter of 2026. Subject to approval, the first EU launch under the YUVIWEL brand is planned in Germany for the first quarte